Abstract: Objective To investigate the value of carrelizumab combined with chemotherapy in conversion therapy of primary unresectable locally advanced esophageal cancer.Methods A descriptive case series study was used to retrospectively analyze 22 patients with unresectable locally advanced esophageal squamous cell carcinoma who underwent conversion therapy from February 2020 to December 2021.They were treated with “carrelizumab + albumin paclitaxel+cisplatin” regimen for 3 ~ 4 cycles before operation.The patients who were evaluated as radical surgery after multidisciplinary joint consultation were treated with surgery.The effect,adverse reactions and surgical index during conversion therapy were analyzed.Results After conversion therapy,Among the 22 patients,6 had complete remission and 14 had partial remission.The objective remission rate was 90.91%(20/22);16 patients underwent surgery after transformation.The conversion rate was 72.73%(16/22);The resection rate of R0 was 93.75%(15/16).Conclusion Carrelizumab combined with chemotherapy can achieve better clinical remission and higher R0 resection in the conversion therapy of primary advanced unresectable esophageal cancer.

Key words: esophageal cancer, conversion therapy, immunotherapy, chemotherapy